Collaboration empowers healthcare providers with easy access to patient drug history and mission critical information about the medications prescribed on the ZappRx platform
BOSTON--(BUSINESS WIRE)--ZappRx, a healthcare technology company that reduces the administrative burden associated with prescribing specialty medications, today announced a collaboration with FDB (First Databank) to embed its electronic prescribing solution, FDB MedsTracker® eRx, directly into its specialty drug prescribing and prior authorization platform. Announced at the Asembia 2018 Specialty Pharmacy Summit in Las Vegas, where ZappRx is exhibiting in booth 818, the integration speeds delivery of specialty drugs to patients and empowers physicians with increased transparency and easy access to key prescribing information.
The MedsTracker eRx integration will provide clinicians using the ZappRx platform with benefit verification information derived from many of the industry’s largest pharmacy benefit managers (PBM), helping them to better navigate patient drug coverage as well as the ability to e-prescribe through the platform. Collection of medication history will also be streamlined by integration of MedsTracker eRx through its utilization of Surescripts® medication history services. Through use of the MedsTracker eRx platform, ZappRx users will also be leveraging the power of FDB MedKnowledge™ and FDB OrderKnowledge™, industry leading drug knowledge bases that contain a robust level of medication information to assist providers with strategic treatment planning.
“Prescribing specialty drugs can be extremely burdensome and time consuming for all involved. It requires a high degree of transparency and collaboration to reduce the administrative burden on providers to ensure that patients get the medications they need in a timely fashion,” said Zoe Barry, CEO and founder of ZappRx. “Integrating MedsTracker eRx into the ZappRx platform constitutes another significant step toward simplifying and automating the specialty drug prescribing process for all involved.”
ZappRx is a cloud-based platform that organizes what is currently a multi-step, manual prescribing process, often involving multiple platforms for each of several treatments, into a single, digitally-enabled format. This allows providers who treat complex conditions to dedicate more time to patient care and spend less on the paperwork required to get patients on therapy. MedsTracker eRx will bolster the ZappRx platform with easy access to medication histories, drug formularies and drug knowledge, further streamlining the prior authorization process.
“Specialty pharmaceuticals are changing healthcare by providing viable options for previously untreatable conditions. While the impact of these innovative therapies can be huge, their potential is only as great as our ability to get them into the hands of patients,” said Dewey Howell, MD, PhD, Vice President of Clinical Applications, FDB. “By focusing on specialty pharmaceutical prescribing, ZappRx, integrated with FDB MedsTracker, will be taking on one of the most complex and cumbersome prescribing processes in healthcare. We are excited to help ZappRx advance their mission of getting lifesaving drugs to the patients who need them the most.”
To learn more about ZappRx and the work it is doing to improve care for patients in need, visit them online at www.zapprx.com. Attendees of the 2018 Asembia Specialty Pharmacy Summit can visit ZappRx at booth 818 to learn more about its platform and or the integration with MedsTracker eRx.
ZappRx streamlines the complex process required to order specialty medications, increasing efficiencies when collecting and maintaining the myriad requisite information for specialty prescribing — including pharmacy information, payer/prior authorization requirements, and relevant clinical history. ZappRx then enables providers, pharmacists, and payers to digitally interact with one another to fill a prescription, reducing the need for faxes and phone calls. The platform is currently live in three disease areas, including Pulmonary Arterial Hypertension (PAH), Idiopathic Pulmonary Fibrosis (IPF), and Cystic Fibrosis, with plans to expand to support prescribing for other areas, including gastroenterology, rheumatology, neurology, and oncology conditions.
About FDB (First Databank)
FDB is the leading provider of drug and medical device knowledge that helps healthcare professionals make precise decisions. With thousands of customers worldwide, FDB enables our information system developer partners to deliver valuable, useful, and differentiated solutions. We offer more than three decades of experience in transforming medical knowledge into actionable, targeted, and effective solutions that help improve patient safety, operational efficiency, and healthcare outcomes. For a complete look at our solutions and services, please visit www.fdbhealth.com or follow us on Twitter and LinkedIn.